-
![3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS](/abs-image/US/2007/11/15/US20070265252A1/abs.jpg.150x150.jpg)
11.发明申请3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS 有权3,4-二氢-2H-苯并[1,4]氧杂和噻吩衍生物作为CETP抑制剂公开(公告)号：US20070265252A1
公开(公告)日：2007-11-15
申请号：US11746776
申请日：2007-05-10
Applicant: Gee-Hong Kuo , Aihua Wang , Thomas Rano , Catherine Prouty , Keith T. Demarest , Patricia Pelton
Inventor： Gee-Hong Kuo , Aihua Wang , Thomas Rano , Catherine Prouty , Keith T. Demarest , Patricia Pelton
IPC: A61K31/54 , A61K31/535 , C07D279/16 , C07D265/36
CPC classification number: C07D265/36 , C07D279/16
Abstract: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Abstract translation: 本发明涉及用作CETP抑制剂的本文所述的式（I）化合物，含有它们的组合物及其使用方法。
-
公开(公告)号：US20070219245A1
公开(公告)日：2007-09-20
申请号：US11685247
申请日：2007-03-13
Applicant: Cuifen Hou , Yin Liang , Keith T. Demarest , Druie E. Cavender , Michael P. Wachter , Mingde Xia
Inventor： Cuifen Hou , Yin Liang , Keith T. Demarest , Druie E. Cavender , Michael P. Wachter , Mingde Xia
IPC: A61K31/4545
CPC classification number: A61K31/4545
Abstract: The present invention is directed to a method for use of substituted dipiperidine compounds of Formula (I) or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists, for preventing, treating or ameliorating syndromes, disorders or diseases related to CCR2 activation in a subject in need thereof.
Abstract translation: 本发明涉及一种使用作为CCR2拮抗剂的式（I）的取代二哌啶化合物或其盐，异构体，前药，代谢物或多晶型物，用于预防，治疗或改善综合征，疾病或与 CCR2在有需要的受试者中的活化。
-
13.发明授权Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators 有权包含葡萄糖再吸收抑制剂和类视色素-X受体调节剂的组合疗法公开(公告)号：US06838442B2
公开(公告)日：2005-01-04
申请号：US10115725
申请日：2002-04-03
Applicant: Jacqueline C. Bussolari , Xiaoli Chen , Bruce R. Conway , Keith T. Demarest , Hamish N. M. Ross , Rafael Severino
Inventor： Jacqueline C. Bussolari , Xiaoli Chen , Bruce R. Conway , Keith T. Demarest , Hamish N. M. Ross , Rafael Severino
IPC: A61K45/06 , A61K31/203 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/70 , A61K31/7048 , A61P1/00 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P25/00 , A61P27/02 , A61P27/12 , A61P29/00 , A61P43/00 , A61K38/28
CPC classification number: A61K31/425 , A61K31/203 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/70 , Y10S514/866 , A61K2300/00
Abstract: Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.
Abstract translation: 公开了包含用于治疗糖尿病和综合征X的RXR调节剂和葡萄糖再吸收抑制剂的组合疗法。
-
![3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors](/abs-image/US/2011/09/06/US08012963B2/abs.jpg.150x150.jpg)
14.发明授权3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors 有权3,4-二氢-2H-苯并[1,4]恶嗪和噻嗪衍生物作为CETP抑制剂公开(公告)号：US08012963B2
公开(公告)日：2011-09-06
申请号：US12782280
申请日：2010-05-18
Applicant: Gee-Hong Kuo , Thomas Rano , Aihua Wang , Catherine Prouty , Keith T. Demarest , Patricia Pelton
Inventor： Gee-Hong Kuo , Thomas Rano , Aihua Wang , Catherine Prouty , Keith T. Demarest , Patricia Pelton
IPC: A61K31/536
CPC classification number: C07D265/36 , C07D279/16
Abstract: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Abstract translation: 本发明涉及用作CETP抑制剂的本文所述的式（I）化合物，含有它们的组合物及其使用方法。
-
公开(公告)号：US20100331406A1
公开(公告)日：2010-12-30
申请号：US12873383
申请日：2010-09-01
Applicant: Alan DEANGELIS , Keith T. Demarest , Gee-Hong Kuo , Patricia Pelton , Aihua Wang , Rui Zhang
Inventor： Alan DEANGELIS , Keith T. Demarest , Gee-Hong Kuo , Patricia Pelton , Aihua Wang , Rui Zhang
IPC: A61K31/275 , A61K31/192 , C07C59/135 , C07C255/41 , A61P3/10 , A61P1/00 , A61P3/06 , A61P3/04 , A61P9/10 , A61P9/00 , A61P13/12
CPC classification number: C07C323/60 , C07C59/68 , C07C323/20
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
Abstract translation: 本发明具有4 - （（苯氧基烷基）硫基） - 苯氧基乙酸及其类似物，含有它们的组合物，以及使用它们作为PPAR调节剂来治疗或抑制例如血脂异常进展的方法。
-
Patent Agency Ranking
公开(公告)号：US07812053B2
公开(公告)日：2010-10-12
申请号：US11226179
申请日：2005-09-14
Applicant: Alan DeAngelis , Keith T. Demarest , Gee-Hong Kuo , Patricia Pelton , Aihua Wang , Rui Zhang
Inventor： Alan DeAngelis , Keith T. Demarest , Gee-Hong Kuo , Patricia Pelton , Aihua Wang , Rui Zhang
IPC: A61K31/192 , C07C323/22
CPC classification number: C07C323/60 , C07C59/68 , C07C323/20
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
Abstract translation: 本发明具有4 - （（苯氧基烷基）硫基） - 苯氧基乙酸及其类似物，含有它们的组合物，以及使用它们作为PPAR调节剂来治疗或抑制例如血脂异常进展的方法。
-
![3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors](/abs-image/US/2010/07/06/US07749995B2/abs.jpg.150x150.jpg)
17.发明授权3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors 有权3,4-二氢-2H-苯并[1,4]恶嗪和噻嗪衍生物作为CETP抑制剂公开(公告)号：US07749995B2
公开(公告)日：2010-07-06
申请号：US11746776
申请日：2007-05-10
Applicant: Gee-Hong Kuo , Aihua Wang , Thomas Rano , Catherine Prouty , Keith T. Demarest , Patricia Pelton
Inventor： Gee-Hong Kuo , Aihua Wang , Thomas Rano , Catherine Prouty , Keith T. Demarest , Patricia Pelton
IPC: C07D413/04 , C07D413/12 , A61K31/536
CPC classification number: C07D265/36 , C07D279/16
Abstract: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Abstract translation: 本发明涉及用作CETP抑制剂的本文所述的式（I）化合物，含有它们的组合物及其使用方法。
-
18.发明申请BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL 有权作为用于增加HDL-C，低LDL-C和较低胆固醇的PPAR-DELTA激动剂的苯扎维林氧化胆酸衍生物公开(公告)号：US20070244094A1
公开(公告)日：2007-10-18
申请号：US11736221
申请日：2007-04-17
Applicant: Gee-Hong Kuo , Yan Zhang , Lan Shen , Songfeng Lu , Keith T. Demarest , Patricia Peiton
Inventor： Gee-Hong Kuo , Yan Zhang , Lan Shen , Songfeng Lu , Keith T. Demarest , Patricia Peiton
IPC: A61K31/55 , C07D417/02 , C07D409/02 , C07D413/02 , C07D403/02 , C07D405/02
CPC classification number: C07D409/06 , C07D223/16 , C07D403/06 , C07D405/06 , C07D413/06 , C07D417/06
Abstract: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.
Abstract translation: 本发明涉及用作PPAR激动剂的式（I）化合物。 治疗一种或多种病症的药物组合物和方法，包括但不限于糖尿病，肾病，神经病，视网膜病，多囊卵巢综合症，高血压，缺血，中风，肠易激综合征，炎症，白内障，心血管疾病，代谢综合症， 还描述了使用本发明化合物的高LDL-胆固醇血症，血脂异常（包括高甘油三酯血症，高胆固醇血症，混合性高脂血症和低HDL-胆固醇血症），动脉粥样硬化，肥胖症和与脂质代谢相关的其它障碍和能量内环境平衡并发症。
-
公开(公告)号：US07928238B2
公开(公告)日：2011-04-19
申请号：US11746755
申请日：2007-05-10
Applicant: Thomas Rano , Gee-Hong Kuo , Ellen Sieber-McMaster , Keith T. Demarest , Patricia Pelton , Aihua Wang
Inventor： Thomas Rano , Gee-Hong Kuo , Ellen Sieber-McMaster , Keith T. Demarest , Patricia Pelton , Aihua Wang
IPC: C07D453/04 , A01N43/42
CPC classification number: C07D215/12 , C07D215/04 , C07D215/14 , C07D401/04 , C07D409/04
Abstract: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Abstract translation: 本发明涉及用作CETP抑制剂的本文所述的式（I）化合物，含有它们的组合物及其使用方法。
-
20.发明申请USE OF ALPHA-METHYLGLUCOSIDE (AMG) AS AN INDICATOR FOR GLUCOSE ABSORPTION AND EXCRETION 有权作为葡萄糖吸收和放出的指示剂使用阿尔法 - 甲基葡糖苷（AMG）公开(公告)号：US20110065200A1
公开(公告)日：2011-03-17
申请号：US12881695
申请日：2010-09-14
Applicant: Keith T. Demarest , James M. Lenhard , Gregory C. Leo , Yin Liang , Tonya L. Martin
Inventor： Keith T. Demarest , James M. Lenhard , Gregory C. Leo , Yin Liang , Tonya L. Martin
IPC: G01N33/50
CPC classification number: G01N33/5088 , A61K49/0004 , Y10T436/142222
Abstract: Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.
Abstract translation: 这里提出的是在体内使用α-甲基葡糖苷（AMG）作为胃肠道（GI）系统葡萄糖吸收的指示剂或口服AMG后尿液中的葡萄糖排泄的方法。 该方法可用于例如但不限于确定动物中钠依赖性葡萄糖转运蛋白（SGLT）抑制剂的作用，比较动物中第一和第二SGLT抑制剂的作用的差异，以及 诊断与胃肠道（GI）系统的葡萄糖吸收相关的疾病或来自动物的肾脏的葡萄糖排泄。
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.029 seconds)
